Podcasts about Ramalingam

Results of the phase 3 LAURA clinical trial, presented at the 2024 American Society of Clinical Oncology Annual Meeting, showed that osimertinib significantly improves progression-free survival in patients with unresectable stage III EGFR-mutant non-small cell lung cancer (NSCLC) after chemoradiotherapy. “The benefits of osimertinib in this patient population when compared to placebo are just incredibly dramatic,” noted Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. He spoke with lead study author Suresh S. Ramalingam, MD, the Roberto C. Goizueta Distinguished Chair for Cancer Research and the executive director at the Winship Cancer Institute of Emory University in Atlanta, about how oncologists should adjust their practice in the wake of these key findings. Dr. Ramalingam tackled questions about the optimal duration of osimertinib therapy, toxicity concerns, and notable benefits seen in the LAURA data. “Osimertinib reduced both intrathoracic progression and extrathoracic progression, particularly intracranial progression,” he noted. Dr. Ramalingam reported research funding from Amgen, AstraZeneca/MedImmune, Bristol Myers Squibb, Merck, Pfizer, and Takeda; travel, accommodations, and other expenses from AbbVie; and a relationship with the American Cancer Society. Dr. Figlin reported various financial relationships.

An engineer with a passion for science and mechanics, when Sri V Ramalingam heard about Bhagawan materialising Vibhuti and other objects, he dismissed him right away as a magician. This was in late 60s. In the early 70s, a colleague gave him a book about Bhagawan. He felt the book was too good to be true, it seemed like a fantasy to him. However, when an opportunity knocked for him to visit Prasanthi Nilayam, he decided to take that chance to investigate himself directly and then come to his final conclusions. And as they say, "He came, he saw and he was conquered." Conquered by the aura of Sai, overwhelmed by His omniscience and transformed by the touch of His love. This is the thrilling tale of Sri V Ramalingam who has been serving in the Sri Sathya Sai Information Technology Centre of Prasanthi Nilayam since 2003. Even though he is an octogenarian now, he continues to be active in His divine mission.

This week's episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.03.31.535026v1?rss=1 Authors: Deolal, P., Ramalingam, K., Das, B., Mishra, K. Abstract: When yeast cells are exposed to nutrient-limiting conditions, they undergo transcriptional and translational reprogramming that results in the remodeling of metabolite utilization and organelle architecture. Organelle membranes and contacts also undergo structural and functional alterations. In the budding yeast Saccharomyces cerevisiae, regulated expression of Uip4 is shown to be a critical effector of nuclear shape and function, particularly during the stationary phase. In this work, we demonstrate that the absence of UIP4 affects the morphology of multiple other organelles including mitochondria, endoplasmic reticulum, vacuole and the distribution of lipid droplets. The results show that modulating carbon source, nitrogen availability and cellular energy state impact Uip4 expression. This expression of Uip4 is controlled by the transcription factor Msn2, downstream of Sch9 signaling pathway. Cells lacking Uip4 have poor survival in the stationary phase of the growth cycle. These cellular changes are concomitant with dysregulation of the global lipidome profile and aberrant organelle interaction. We propose that the dynamic and regulated expression of Uip4 is required to maintain lipid homeostasis and organelle architecture which is ultimately required to survive in nutrient-limiting conditions such as stationary phase. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Kelly connects with Ben Ramalingam, who just became the Director of Strategy for the British Red Cross and has been a senior leader, innovator, and researcher specializing in international crisis management and development. His new book is called “Upshift: Turning Pressure into Performance and Crisis into Creativity.”

In this KEEN ON episode, Andrew talks to UPSHIFT author Ben Ramalingam on how to turn pressure into performance and crisis into creativity. Ben Ramalingam is a senior leader, innovator, and researcher specializing in international crisis management and development. He is the executive director of the United Kingdom Humanitarian Innovation Hub and has worked with and advised the United Nations, the World Bank, national and regional governments, nongovernmental organizations, and businesses. In 2020 he was named a Humanitarian Change Maker of the 2010s, as one of the ten people or organizations who had done most to improve international humanitarian work over the course of the decade. He is the author of Aid on the Edge of Chaos: Rethinking International Cooperation in a Complex World and Upshift: Turning Pressure into Performance and Crisis into Creativity. Name as one of the "100 most connected men" by GQ magazine, Andrew Keen is amongst the world's best known broadcasters and commentators. In addition to presenting KEEN ON, he is the host of the long-running How To Fix Democracy show. He is also the author of four prescient books about digital technology: CULT OF THE AMATEUR, DIGITAL VERTIGO, THE INTERNET IS NOT THE ANSWER and HOW TO FIX THE FUTURE. Andrew lives in San Francisco, is married to Cassandra Knight, Google's VP of Litigation & Discovery, and has two grown children. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode, Gino is with Nirmal Ramalingam. Nirmal shares how he got started in the multifamily real estate investment. He shares the hardhips and struggles he had before joining the Jake and Gino comunity and how he transitioned into pro-investor after joining it. Nirmal started as a software development manager and then begun as a real estate investor. He is currently the managing partner at Blue Wheel Partners, the company that focuses on buying Commercial Multi-Family assets at the right price with a value add component to really provide extensive upside to our investors. Key Insights: 00:00 Introduction 06:10 Challenges before joining the community 08:02 Views about Denver real estate market 11:09 Deteremining to join the Jake and Gino community 14:45 Getting your spouse into what you are working on 19:32 Right time to begin with real estate investing 25:12 leveraging the next opportunity while working on goals 28:29 Wrap-up We're here to help create multifamily entrepreneurs... Here's how: Brand New? Start Here: https://jakeandgino.mykajabi.com/free-wheelbarrowprofits Want To Get Into Multifamily Real Estate Or Scale Your Current Portfolio Faster? Apply to join our PREMIER MULTIFAMILY INVESTING COMMUNITY & MENTORSHIP PROGRAM. (*Note: Our community is not for beginner investors) https://jakeandgino.com/apply About Jake & Gino Jake & Gino are multifamily investors, operators, and mentors who have created a vertically integrated real estate company. They own over 1900 units totaling over $250M in assets under management. Their students have closed on more than 55,000 units totaling over $5 Billion in assets. They have created the Jake & Gino Premier Multifamily Community to teach others a simple three-step framework for investing in multifamily real estate. Connect with Jake & Gino on the social media platform you are most active on: Jake & Gino Facebook: https://www.facebook.com/jakeandgino/ Jake & Gino Linkedin: https://www.linkedin.com/company/jake-and-gino Jake & Gino Instagram: https://www.instagram.com/jakeandgino/ #realestate #multifamilyrealestate #multifamilyinvesting #investing #apartmentinvesting #multifamily #realestateinvesting #commercialrealestate #loopnet #costart #biggerpockets #realestateinvest #multifamilyapartment #apartmentbuildings #multifamilydeals #multifamilyanalysis #analyzemultifamily #Multifamilyunderwriting #multifamilycommunity #multifamilyinvestors

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.08.515615v1?rss=1 Authors: Lam, I., Ndayisaba, A., Lewis, A. J., Fu, Y., Sagredo, G. T., Zaccagnini, L., Sandoe, J., Sanz, R. L., Vahdatshoar, A., Martin, T. D., Morshed, N., Ichihashi, T., Tripathi, A., Ramalingam, N., Oettgen-Suazo, C., Bartels, T., Schabinger, M., Hallacli, E., Jiang, X., Verma, A., Tea, C., Wang, Z., Hakozaki, H., Yu, X., Hyles, K., Park, C., Theunissen, T. W., Wang, H., Jaenisch, R., Lindquist, S., Stevens, B., Stefanova, N., Wenning, G., Luk, K. C., Sanchez Pernaute, R., Gomez-Esteban, J. C., Felsky, D., Kiyota, Y., Sahni, N., Yi, S. S., Chung, C.-Y., Stahlberg, H., Ferrer, I., Schoneberg, J., Ell Abstract: In neurodegenerative proteinopathies, intracellular inclusions are histopathologically and ultrastructurally heterogeneous but the significance of this heterogeneity is unclear. Patient- derived iPSC models, while promising for disease modeling, do not form analogous inclusions in a reasonable timeframe and suffer from limited tractability and scalability. Here, we developed an iPSC toolbox that utilizes piggyBac-based or targeted transgenes to rapidly induce CNS cells with concomitant expression of misfolding-prone proteins. The system is scalable and amenable to screening and longitudinal tracking at single-cell and single-inclusion resolution. For proof-of- principle, cortical neuron alpha-synuclein inclusionopathy models were engineered to form inclusions spontaneously or through exogenous seeding by alpha-synuclein fibrils. These models recapitulated known fibril- and lipid-rich inclusion subtypes in human brain, shedding light on their formation and consequences. Genetic-modifier and protein-interaction screens identified sequestered proteins in these inclusions, including RhoA, that were deleterious to cells when lost. This new iPSC platform should facilitate biological and drug discovery for neurodegenerative proteinopathies. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Well-known orator and advocate T Ramalingam is coming to Australia soon to deliver a Keynote speech at the annual literary event organised by Tamil Arts and Culture Association Inc (TACA, Sydney. This is an interview with him. - சிட்னியில் தமிழ்க் கலை மற்றும் பண்பாட்டுக் கழகம் நடத்தும் இனிய இலக்கிய சந்திப்பு, எதிர்வரும் நவம்பர் 6ம் திகதி Sydney Durga Auditorium இல் பிற்பகல் 6 மணிக்கு நடைபெறவுள்ளது. இந்நிகழ்வில் தமிழகத்தின் பிரபல சொற்பொழிவாளர் 'இலக்கியச்சுடர்' த இராமலிங்கம் பங்கேற்கவுள்ளார். அவருடன் ஒரு உரையாடல். உரையாடுபவர் றேனுகா துரைசிங்கம்.

Episode 3 of Brown Bag, a podcast on social media, politics and society from a Global South perspective, hosted by ICT4Peace Foundation's Special Advisor Dr Sanjana Hattotuwa. In this episode, Hattotuwa speaks with Vidhya Ramalingam, Founder and CEO of Moonshot. This production of this podcast series is supported by the Daniel Gablinger Foundation.

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, including key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Harold Burstein, Ibiayi Dagogo-Jack, Rafael Fonseca, Brad Kahl, Rutika Mehta, Craig Moskowitz, Joyce O'Shaughnessy, Krina Patel, Philip Philip, Suresh Ramalingam and Sandy Srinvas, moderated by Dr Neil Love.

Dr. Marina Garassino and Dr. Suresh Ramalingam join Lung Cancer Considered host Dr. Narjust Florez to share experiences as international medical graduates. Dr. Garassino is an internationally recognized expert in the treatment of thoracic malignancies from the Medical School of Università degli Studi of Milan, Italy, She recently joined the University of Chicago as the chief of the Thoracic Oncology Group. Dr. Suresh Ramalingam is the Executive Director, Winship Cancer Institute of Emory University, the Roberto C. Goizueta Distinguished Chair for Cancer Research, and a professor of medicine at Emory University School of Medicine.

On this episode, PrecisCa speaks with Dr. Suresh Ramalingam, medical oncologist and Executive Director at the Winship Cancer Institute of Emory University in Atlanta, Georgia.   Dr. Ramalingam sits down with us to answer the following questions: What is the prognosis of lung cancer by stage? What are the side effects of targeted therapy for lung cancer & how do you manage them? Do you ever use immunotherapy in patients with driver mutations? What are the concerns about sequencing of immunotherapy and targeted agents? How do you treat metastatic EGFR mutated lung cancer in First, Second and Third line settings? How do you approach brain metastases in EGFR-mutated lung cancer? What are the modalities that can be used to treat brain metastases and how do the different TKI's compare in terms of brain metastases? What are the benefits of enrolling in a clinical trial? Board certified in medical oncology, Suresh S. Ramalingam, MD, FACP, FASCO, is nationally recognized as an investigator and a physician in the area of small cell and non-small cell lung cancer. Dr. Ramalingam serves as executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center. He is past-president of the Georgia Society of Oncology and a member of the board of Georgia CORE. He is a Fellow of the American Society of Clinical Oncology and a Georgia Cancer Coalition Distinguished Cancer Scholar. Dr. Ramalingam holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, and International Association of Lung Cancer Study. He plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair of Therapeutics Programs. He serves on several international, national and institutional committees. He is a member of the Medical Oncology Board Exam Committee for American Board of Internal Medicine.  Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos. New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.  

Feedback

Nano Technology

Nano Technology

With the end of the year upon us let's look forward to 2022. I discuss the art of coping with the pandemic as a medic, mother and a professional with a GP colleague Dr Tharshini Ramalingam and we reflect on what makes us whole and how to achieve wellness despite the pandemic. Here are our top tips for wellness: Social contact is the backbone of our existence. Try and find the thing that motivates you in life. Healthcare is self care. The holy grail of wellness is mind, body and spiritual health. All any of us are guaranteed is today, so make each day, your best day. I'd like to thank all our guests for joining our podcast this year and sharing their experiences with our listeners whilst always inspiring us to live a longer, healthier life. Dr Millie December 2021

Suresh Ramalingam, MD, FACP, FASCO, is the Professor of the department of Hematology-Oncology, Roberto C. Goizueta Distinguished Chair and Assistant Dean for Cancer Research, Director of Division of Medical Oncology at Emory University School of Medicine. He is also the Deputy Director at Winship Cancer Institute of Emory University. Dr Ramalingam completed his medical school from Kilpauk Medical College University of Madras and residency in Internal Medicine from Wayne State University. He pursued a fellowship in Hematology and Medical Oncology from University of Pittsburgh Cancer Institute. Dr. Ramalingam currently serves as president of the Georgia Society of Oncology. Dr. Ramalingam is nationally recognized as an investigator and a physician in the area of small cell and non-small cell lung cancer. He has been awarded the James Eckman Award for Excellence in Teaching at Emory, and the NCI Cancer Clinical Investigator Team Leadership Award. What makes an exceptional mentor and how do you go about finding one? Dr. Suresh Ramalingam explains why enthusiasm and your ability to “do the homework before you go to someone” compel the most impactful mentors to pay it forward, investing in improving the lives of patients not only by their own efforts, but also by the future efforts of those who share in their wisdom. Listen to Dr. Ramalingam's unique journey from Chennai to Atlanta to learn more about how identifying your strengths, knowing your gaps, and doing your homework can initiate meaningful mentorships and propel your career in medicine.   Pearls of Wisdom: 1. You don't need to reinvent the wheel. You need to learn how to reach out and move it forward in a way that helps you progress in your career and life. 2. Focusing on your strengths first gives you the confidence to objectively look at your gaps and figure out who can help you fill them. 3. To approach the right mentor, invest in learning first and realizing why you need a mentor in the first place.

What happened to Mookan? What favour did Ramalingam ask the boy? What did he offer for that? Why didn't the boy accept what Ramalingam gave? Whom did he ask to intervene? What did Dhanasekaran do to resolve the issue?மூக்கனுக்கு என்ன ஆனது? ராமலிங்கம் பையனிடம் என்ன உதவி கேட்டார்? அதற்கு என்ன தருவதாக சொன்னார்? ராமலிங்கம் தந்ததை பையன் ஏன் வாங்க மறுத்தான்? அவர் யாரிடம் முறையிட்டார்? பிரச்னையை தீர்க்க தனசேகரன் என்ன செய்தார்?Youtube Story Link: https://youtu.be/fXTMCizTYo0 You can listen to this show and other awesome shows on the new and improved IVM Podcast App on Android: https://ivm.today/android or iOS: https://ivm.today/iosYou can check out our website at http://www.ivmpodcasts.com

Ramalingam Subramanian is the Head of Brand and Communications at CoinDCX – India's largest and safest cryptocurrency exchange platform. He has extensive experience working as a Brand Consultant with various industry leaders, SMEs, and young startups. Previously, Ramalingam worked as a Managing Partner for Prarambhan Creative Works. Welcome to the 53rd episode of The Mini Adult Troubles where we talked about how CoinDcx plans their marketing campaign, crypto industry in the next 5 years, and a lot more. Connect with Ramalingam Subramanian: LinkedIn: https://in.linkedin.com/in/ramsub Connect with Ayush: My Instagram: https://www.instagram.com/ayushshukl.... My Twitter: https://twitter.com/ayushshukl99​​​​​

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

“I'm a big believer that the internet can be a force for good and that there's a lot of power in the connections that can be formed online.” -- Vidhya RamalingamWe've talked before about how the internet and social media can spread disinformation and hate-related posts but how can it also be used for good? My guest this week is Vidhya Ramalingam, CEO and Founder of Moonshot, a company that uses technology to identify people at risk of violent extremism. Moonshot repurposes target advertising methods to intervene by connecting those people with humans who can help."If it's human connections that are gonna get people out of these movements, then actually facilitating those connections (...) that's something that we can replicate and we can scale," Ramalingam said.Her journey to founding Moonshot is pretty unique. She started by attending white nationalist rallies in Sweden and having personal conversations with people involved in the movements. She was surprised by what she learned.

#PulavarRamalingam #புலவர்ராமலிங்கம் #tamilculture #Pattimandram #பட்டிமன்றம்

In this episode, we talk with Vinolee Ramalingam!! Vinolee Ramalingam is an inspiration to many women from all around India. She was an athletic kid who won medals at national level until higher studies put them at the back burner. An M.Tech graduate and an assistant professor, she picked up sport to lose weight after the birth of her son. Little did she know that it will rekindle her childhood passion for sport and completely change the course of her life. She completed 3 Ironman events and multiple half Ironman events. She gave up her job as a lecturer and became an Ironman certified triathlon coach helping others push their limits in swimming, running and cycling with TriLeeCoaching. This episode covers: 0:00:00 Intro 0:03:40 Trilee coaching 0:04:45 Initial days in sport as a kid 0:14:48 Focus on education - sport taking the backseat 0:19:10 Start of sport again - CTC Triathlon 0:33:40 Full Ironman event in Barcelona 2017 0:43:30 Cairns Ironman 2019 0:55:30 Nice 70.3 World Championships 1:07:40 Decision to quit the day job 1:11:40 Coaching work, training and family Some Links Below: Working Athlete Community on FB. Link to Anchor Voice messages About the Podcast The working athlete podcast is a podcast with and for working athletes from all walks of life and various sports. The goal is to provide inspiration, training tips, mental hacks, time management and life-style advice through conversations with some of the best in sport, from athletes to coaches. If you think you can benefit from this, please consider subscribing so that you don't miss the weekly episodes in future. Who is a working athlete? Someone working full-time/part-time, entrepreneur or anyone who has to work to make ends meet and doesn't let being busy to stop him/her from pursuing an active lifestyle is a working athlete. I consider stay at home moms/dads who pursue a sport, as working athletes because homemaking is a full-time job. If you like this, share with friends who could be interested. For the visually inclined, a video version of the podcast can be found here: YouTube Other Places you'll find the podcast on: Anchor | RSS | Apple Podcasts | Spotify | Google podcasts | Pocket Casts | Radio Public | Breaker A bit about myself: I'm Venkat/Venkateswara Rao in my work avatar, working as a Chief Data Analyst in the IT industry in Bangalore. I'm Venky/Bikeyvenky for my friends in the cycling community.

This program includes faculty lectures by Drs Suresh S Ramalingam of Emory University School of Medicine and Gregory J Riely of Memorial Sloan Kettering Cancer Center on the treatment algorithm for advanced non-small cell lung carcinoma (NSCLC) and the current management of NSCLC and small cell lung cancer. Access NCPD information and select publications here.

Hello! Welcome to the new podcast of CDMC!! This week’s podcast is with Mr. Ramalingam Subramanian, Recognized as a brand change agent, persistent innovator, and problem solver who has championed some of the most successful brand strategies and product launch campaigns, he comes with a strong entrepreneurial as well as corporate experience handling brands, products, product teams as well as commercial product releases. Mr. Ramalingam has considerable experience working as a Brand Consultant with various industry leaders, SMEs as well as young startups. Creating a brand strategy, laying out the campaign plans as well as creating, developing, managing and delivery on Marketing Plans have been his forte. Mr. Ramalingam is currently working as Head of Brand and Communications with CoinDCX and is open to take teaching and speaking assignments. Tune in to this interesting episode where u get deep insights on what’s happening on industry’s forefront!

Chairperson of MERCY Malaysia Sabah and medical doctor at Ministry of Health, Dr Anbarasu Ramalingam joined Bel and JD on #TheLITEBreakfast this morning.He shared the COVID-19 situation in Sabah and how his hospitals are handling the pandemic.

Recent Advances in Medical Oncology: Targeted Therapy for Lung Cancer — Faculty Presentation 1: Contemporary Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Ramalingam. CME information and select publications

More about Our Guesthttps://researchers.anu.edu.au/researchers/grabosky-pnFrom this Episode:Michael A. Sussmann, (1999) The Critical Challenges from International High-Tech and Computer-Related Crime at the Millennium, 9 Duke Journal of Comparative & International Law 451-489https://scholarship.law.duke.edu/djcil/vol9/iss2/5/Kim Dotcomhttps://en.wikipedia.org/wiki/Kim_DotcomMalaysian Cybercrime LawYew, Wong Malaysian Law and Computer Crime (SANS Reading Room Whitepaper)https://www.sans.org/reading-room/whitepapers/legal/malaysian-law-computer-crime-670Appudurai, J., & Ramalingam, C. L. (2007). Computer Crimes: A Case Study of What Malaysia Can Learn from Others?. Journal of Digital Forensics, Security and Law, 2(2), 1.https://commons.erau.edu/cgi/viewcontent.cgi?article=1020&context=jdfslDrink or Diehttps://en.wikipedia.org/wiki/DrinkOrDieSanger, David E. (2018)The Perfect Weapon: War, Sabotage, and Fear in the Cyber AgeBruce Sterling The Hacker Crackdown: Law and Disorder on the Electronic Frontier (1992)

Vidhya brings her offline anthropology background to the digital space. In conversation with Oren Segal, she brings empathy to understanding extremist movements. They talk about evidenced-based social work interventions and more.“If relationships get people into these movements, relationships can get them out.” Vidhya Ramalingam is the co-Founder of Moonshot CVE, a company using technology to disrupt and counter violent extremism globally. She directs overall strategy and oversees campaigns, software development, and digital projects in over 25 countries.More on GW Program on extremism here: http://moonshotcve.com/ Stay engaged and follow along for more:Stay engaged and follow along for more on Twitter at @OrenSegal @ADL and @PERIL_AU

This week we head to Chennai, India and speak with Anitha Ramalingam. She shares her journey with yoga and how the practice can be used to deepen the connection of mind, body, energy and spirit.  You can find her here: IG @yoga_with_anitha www.yogawithanitha.in

Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.